Ortiz-Morales, M.J.; Toledano-Fonseca, M.; Mena-Osuna, R.; Cano, M.T.; Gómez-España, A.; Haba-RodrÃguez, J.R.D.l.; RodrÃguez-Ariza, A.; Aranda, E.
Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab. Cancers 2022, 14, 3054.
https://doi.org/10.3390/cancers14133054
AMA Style
Ortiz-Morales MJ, Toledano-Fonseca M, Mena-Osuna R, Cano MT, Gómez-España A, Haba-RodrÃguez JRDl, RodrÃguez-Ariza A, Aranda E.
Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab. Cancers. 2022; 14(13):3054.
https://doi.org/10.3390/cancers14133054
Chicago/Turabian Style
Ortiz-Morales, M. José, Marta Toledano-Fonseca, Rafael Mena-Osuna, M. Teresa Cano, Auxiliadora Gómez-España, Juan R. De la Haba-RodrÃguez, Antonio RodrÃguez-Ariza, and Enrique Aranda.
2022. "Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab" Cancers 14, no. 13: 3054.
https://doi.org/10.3390/cancers14133054
APA Style
Ortiz-Morales, M. J., Toledano-Fonseca, M., Mena-Osuna, R., Cano, M. T., Gómez-España, A., Haba-RodrÃguez, J. R. D. l., RodrÃguez-Ariza, A., & Aranda, E.
(2022). Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab. Cancers, 14(13), 3054.
https://doi.org/10.3390/cancers14133054
